Currently, the combination of trastuzumab and bevacizumab in the first line treatment of HER2/neu positive breast cancer is not justified since there are other anti-HER2 drug combinations that have shown more striking results at least in the metastatic setting.21,22. This evidence concerns the gene ERBB2 and breast carcinoma.